Hepatitis C Infection Clinical Trial
Official title:
Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.
PRIMARY OBJECTIVES:
I. To determine the safety profile of the HCV DNA vaccine, consisting of INO-8000 (HCV
antigen DNA) alone or co-administered with INO-9012 (interleukin [IL]-12 adjuvant DNA) (DNA
plasmid encoding interleukin-12 INO-9012) II. To identify a dose of INO-9012 (IL-12 adjuvant
DNA) for co-administration with INO-8000 (HCV antigen DNA) based on induction of
HCV-specific interferon (IFN)-gamma production by peripheral blood mononuclear cells at 26
weeks compared to baseline in HCV-infected participants.
SECONDARY OBJECTIVES:
I. Determine the rate at which INO-8000 with different doses of INO-9012 induces a > 1 log
decrease (or undetectable) in HCV RNA level at weeks 14 and 26.
II. Determine the rate at which INO-8000 with different doses of INO-9012 induces an
end-of-treatment undetectable HCV ribonucleic acid (RNA) (end-of-treatment virologic
response - EVR) at 26 weeks and a sustained virologic response (SVR) at 36 weeks.
III. Determine the rate at which INO-8000 with different doses of INO-9012 induces other
parameters of cluster of differentiation (CD)8 and CD4 T lymphocyte responses as measured by
flow cytometry, and antibody responses to HCV antigen at weeks 14 and 26.
OUTLINE: This is a dose-escalation study of INO-9012.
Patients receive INO-8000 intramuscularly (IM) and DNA plasmid encoding interleukin-12
INO-9012 IM (dose levels 2-4) followed by electroporation (EP) at day 0 and at weeks 4, 12,
and 24.
After completion of study treatment, patients are followed up at weeks 48 and 76.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01771653 -
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
|
N/A | |
| Recruiting |
NCT03601546 -
Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
|
||
| Completed |
NCT02362217 -
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
|
Phase 1 | |
| Completed |
NCT00513461 -
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
|
Phase 2 | |
| Active, not recruiting |
NCT02143401 -
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
| Completed |
NCT02582632 -
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
|
Phase 3 | |
| Terminated |
NCT01532908 -
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
|
Phase 2 | |
| Recruiting |
NCT01754961 -
Effects of Vitamin D on Inflammation in Liver Disease
|
Phase 2 | |
| Terminated |
NCT01465516 -
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
|
N/A | |
| Completed |
NCT01265511 -
Study of SCY-635, Pegasys and Copegus in Hepatitis C
|
Phase 2 | |
| Completed |
NCT04042740 -
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT05601518 -
Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
|
||
| Terminated |
NCT02429583 -
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
|
Phase 4 | |
| Not yet recruiting |
NCT05506475 -
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
|
||
| Withdrawn |
NCT02112630 -
Boceprevir in End Stage Renal Disease (ESRD)
|
N/A | |
| Terminated |
NCT01841502 -
Interaction Between Paroxetine and Telaprevir
|
Phase 2 | |
| Completed |
NCT02076100 -
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
|
Phase 1 | |
| Completed |
NCT01803308 -
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
|
Phase 1 | |
| Terminated |
NCT01560468 -
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
|
Phase 1 |